On September 15, 2026, women's telehealth company Wisp announced it has served more than two million patients across all 50 U.S. states and named Keira Krausz as chief executive, succeeding Monica Cepak. The milestone and the leadership change arrive together as the deliberate framing for the same strategic move: Wisp is expanding out of the sexual and reproductive health niche it was built on — birth control, STI and UTI care — into fertility, at-home diagnostics, menopause and perimenopause, longevity and healthy ageing, prescription skincare, vaginal probiotics and supplements.

Why It Matters

This is a category signal, not just a company one. Across women's digital health, companies that built scale on one underserved need are now expanding across conditions and life stages — the same week Wisp announced, vaginal-microbiome company Evvy closed a **$40M Series B** to push its diagnostics deeper into fertility medicine. The bet in both cases is that the durable asset isn't the product line, it's the patient relationship, and that whoever owns the woman's health graph from contraception through menopause owns the most valuable direct-to-consumer franchise in the sector. For investors and operators in sexual wellness specifically, there's a strategic caution buried here: sexual and reproductive health increasingly functions as a top-of-funnel product for platforms whose economics live elsewhere. A pure-play sexual health business now competes for the same patient against a company willing to run that service near cost because it monetizes the next fifteen years. And the CEO hire is its own tell — a Purple CMO running a telehealth company means the competitive battleground Wisp has identified is consumer brand and retention, not clinical differentiation.

Krausz comes from direct-to-consumer retail rather than clinical health, having served as chief marketing officer at mattress and wellness brand Purple, which tells you what kind of company Wisp intends to become. "Two million patients is proof that women are looking for a fundamentally different healthcare experience — one that takes them seriously, fits into their lives, and doesn't make them jump through hoops to get the care they need," she said in the announcement. "Wisp has already changed the way millions of women access sexual and reproductive care. Now, we have an opportunity to bring that same experience to more of women's health and build a platform that can be there for them not just for one moment, but for decades."

The infrastructure for the expansion was bought earlier this year. In January 2026, Wisp acquired sexual health provider TBD Health, adding clinical infrastructure and diagnostics capability to the platform. Founded in 2018 and majority-owned by Canadian digital health company WELL Health Technologies, Wisp describes the target end state as a "continuous health-span companion" — a platform women return to as their needs change, rather than a vending machine for individual prescriptions. Women's Tabloid reported that Krausz told MobiHealthNews patients had themselves been asking for support in fertility, perimenopause, menopause and longevity.

The strategic logic is unglamorous and sound. Sexual and reproductive health is a high-frequency, low-stigma-tolerance entry point: it acquires patients cheaply and early, but the episodes are short and the lifetime value is capped. Fertility, menopause and longevity are longer, higher-margin relationships that are far more expensive to acquire cold. Using the first to feed the second is the same playbook Hims & Hers ran from ED into dermatology, weight loss and hormones — with the difference that Wisp is doing it on the women's side of the market, where the equivalent consolidation has been slower and more fragmented.

Sources

Update — 2026-09-18

Initial entry — story first created.